35Pharma
35Pharma creates multi‑specific Activin/GDF ligand traps to treat high‑unmet‑need cardiometabolic and pulmonary diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
35Pharma creates multi‑specific Activin/GDF ligand traps to treat high‑unmet‑need cardiometabolic and pulmonary diseases.
Pulmonary HypertensionHeart FailureObesity
Technology Platform
Multi‑specific protein ligand traps engineered via combinatorial mutagenesis and AI‑assisted design to simultaneously neutralize Activin and GDF ligands.
Opportunities
GSK acquisition provides capital and commercial reach to accelerate HS235’s late‑stage development and expand the ligand‑trap platform into additional cardiometabolic indications.
Risk Factors
Clinical efficacy and safety of multi‑specific ligand traps remain unproven; reliance on a single lead candidate creates concentration risk.
Competitive Landscape
While other firms target the TGF‑β pathway, 35Pharma’s multi‑specific ligand traps offer superior potency and selectivity versus traditional monovalent antibodies, differentiating it from competitors such as Novartis and Roche.